Hypolipidemic, Antioxidant, and Antiinflammatory Activities of Microalgae Spirulina
Open Access
- 5 July 2010
- journal article
- review article
- Published by Wiley in Cardiovascular Therapeutics
- Vol. 28 (4), e33-e45
- https://doi.org/10.1111/j.1755-5922.2010.00200.x
Abstract
Spirulina is free‐floating filamentous microalgae growing in alkaline water bodies. With its high nutritional value, Spirulina has been consumed as food for centuries in Central Africa. It is now widely used as nutraceutical food supplement worldwide. Recently, great attention and extensive studies have been devoted to evaluate its therapeutic benefits on an array of diseased conditions including hypercholesterolemia, hyperglycerolemia, cardiovascular diseases, inflammatory diseases, cancer, and viral infections. The cardiovascular benefits of Spirulina are primarily resulted from its hypolipidemic, antioxidant, and antiinflammatory activities. Data from preclinical studies with various animal models consistently demonstrate the hypolipidemic activity of Spirulina. Although differences in study design, sample size, and patient conditions resulting in minor inconsistency in response to Spirulina supplementation, the findings from human clinical trials are largely consistent with the hypolipidemic effects of Spirulina observed in the preclinical studies. However, most of the human clinical trials are suffered with limited sample size and some with poor experimental design. The antioxidant and/or antiinflammatory activities of Spirulina were demonstrated in a large number of preclinical studies. However, a limited number of clinical trials have been carried out so far to confirm such activities in human. Currently, our understanding on the underlying mechanisms for Spirulina's activities, especially the hypolipidemic effect, is limited. Spirulina is generally considered safe for human consumption supported by its long history of use as food source and its favorable safety profile in animal studies. However, rare cases of side‐effects in human have been reported. Quality control in the growth and process of Spirulina to avoid contamination is mandatory to guarantee the safety of Spirulina products.Keywords
This publication has 102 references indexed in Scilit:
- Spirulinain Clinical Practice: Evidence-Based Human ApplicationsEvidence-Based Complementary and Alternative Medicine, 2011
- Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular riskVascular Health and Risk Management, 2009
- A randomized study to establish the effects of spirulina in type 2 diabetes mellitus patientsNutrition Research and Practice, 2008
- Antihyperlipemic and antihypertensive effects of Spirulina maxima in an open sample of mexican population: a preliminary reportLipids in Health and Disease, 2007
- Anti-inflammatory activity of c-phycocyanin in lipopolysaccharide-stimulated RAW 264.7 macrophagesLife Sciences, 2007
- β-Carotene inhibits inflammatory gene expression in lipopolysaccharide-stimulated macrophages by suppressing redox-based NF-κB activationExperimental & Molecular Medicine, 2005
- Cardiotoxicity of Cancer ChemotherapyPediatric Drugs, 2005
- EFFECTS OF DIETARY Spirulina maxima ON ENDOTHELIUM DEPENDENT VASOMOTOR RESPONSES OF RAT AORTIC RINGSLife Sciences, 1997
- Effect of supplementation of blue green alga (Spirulina) on outcome of pregnancy in ratsPlant Foods for Human Nutrition, 1993
- Lipoprotein-cholesterol distributions in selected North American populations: the lipid research clinics program prevalence study.Circulation, 1980